Press Releases Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Delayed Toronto S.E. Other stock markets 08:48:54 07/05/2024 pm IST			5-day change	1st Jan Change
5.89 ^CAD	-0.51%		+2.08%	+13.49%

22/03	Knight Therapeutics Price Target Raised to $7 at RBC	MT
21/03	Knight Therapeutics Reports Fourth Quarter Results	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City	05:00pm	GL
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call	02/05	GL
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04	GL
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity	28/03	GL
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results	21/03	GL
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call	14/03	GL
Knight Therapeutics Announces Launch of Minjuvi® in Brazil	29/02	GL
Knight Therapeutics Announces Launch of Minjuvi® in Brazil	29/02	AQ
Knight Therapeutics Inc. Celebrates its First Decade of Success	28/02	GL
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil	22/02	GL
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil	22/02	AQ
Knight Therapeutics Announces Launch of Bijuva® in Canada	06/02	GL
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203	25/01	GL
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada	04/01	GL
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada	20/12	AQ
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada	19/12	GL
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada	19/12	AQ
Knight Therapeutics Reports Third Quarter 2023 Results	09/11	GL
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call	02/11	GL
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call	02/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Press Releases

Filters